http://orcid.org/0000-0003-3166-9754
References
- Symmons DP. Neoplasms of the immune system in rheumatic arthritis. Am J Med. 1985;78(1):22–8.
- Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis. 1978;31(11):691–6.
- Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88(3):497–50.
- Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996;32A(10):1753–7.
- Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami H-O, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993;85(4):307–11.
- Hashimoto A, Chiba N, Tsuno H, Komiya A, Furukawa H, Matsui T, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42(4):564–71.
- Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34(2):322–31.
- Yamada K, Oshiro Y, Okamura S, Fujisaki T, Kondo S, Nakayama Y, et al. Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate-associated large B lymphoproliferative disorders. Histopathology. 2015;67(1):70–80.
- Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis:history. Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20–8.
- Tokuhira M, Saito S, Okuyama A, Suzuki K, Higashi M, Momose S, et al. Clinicopathologic investing of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma.2018;59(5):1143–52.
- Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, et al. Brief report: Reversible lymphomas associated with Epstein-Barr virus occurring during therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328(18):1317–21.
- Inui Y, Matsuoka H, Yakushijin K, Okamura A, Shimada T, Yano S, et al. Methotrexate-associated lymphoproliferative disorders:management by watchful waiting and observantion of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015;56(11):3045–51.
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of Haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: International Agency for Reserch on Cancer Press; 2017.
- Calguneri M, Zturk MA, Ozbalkan Z, Akdogan A, Ureten K, Kiraz S, et al. Frequency of lymphadenopathy in rheumatoid arthritis and systemic lupus erythematosus. J Int Med Res. 2003;31(4):345–9.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classifyion criteria: an American College of Rheumatlogy/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010;62(9):2569–81.
- Kanda Y. Investigation of the freely available easy-to-use software `EZR` for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
- Kojima M, Motoori T, Nakamura S. Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. Biomed Pharmacother. 2006;60(10):663–72.
- Asano N, Sato Y. Rheumatoid lymphadenopathy with abundant IgG4(+) plasma cells: a case mimicking IgG4-related disease. J Clin Exp Hematopathol. 2012;52(1):57–9.